Endocrine最新文献

{"title":"Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database.","authors":"Jianxing Zhou, Wei Huang, Yunzhen Xie, Haobin Shen, Maobai Liu, Xuemei Wu","doi":"10.1007/s12020-024-04112-8","DOIUrl":"10.1007/s12020-024-04112-8","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the association between glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and ophthalmic adverse drug reactions (OADRs) using data from the FDA Adverse Event Reporting System (FAERS).</p><p><strong>Methods: </strong>This retrospective pharmacovigilance study analyzed post-marketing FAERS data from 2018 to 2023 to identify GLP-1 RA-related OADRs. This study employed the Weibull model for time-to-onset (TTO) analysis, Bayesian Information Component analysis for disproportionality comparing GLP-1 RAs with other drugs, and the Ω shrinkage method for co-medication analysis.</p><p><strong>Results: </strong>FAERS reported 5003 OADRs associated with GLP-1 RAs, including retinopathy and visual impairment. Disproportionality analysis identified significant signals for semaglutide, liraglutide, and exenatide, suggesting potential associations with OADRs. Co-medication analysis indicated that OADRs primarily resulted from GLP-1 RA use. TTO analysis categorized most OADRs as early failures, emphasizing the need for early monitoring.</p><p><strong>Conclusion: </strong>This study emphasizes the importance of ophthalmic surveillance in patients using GLP-1 RAs, particularly semaglutide, dulaglutide, and exenatide. Enhanced monitoring and patient education are essential for timely detection and management of potential OADRs. Regulatory agencies should consider updating drug labels to include comprehensive warnings about OADRs associated with GLP-1 RA therapies.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"80-90"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A lasso-based model to predict lateral lymph node metastasis in unifocal papillary thyroid carcinoma with central lymph node metastasis.","authors":"Yi Li, Yunhan Ma, Luming Zheng, Qingqing He","doi":"10.1007/s12020-024-04132-4","DOIUrl":"10.1007/s12020-024-04132-4","url":null,"abstract":"<p><strong>Objective: </strong>To screen the risk factors for lateral lymph node metastasis (LLNM) in unifocal papillary thyroid carcinoma (PTC) with central lymph node metastasis (CLNM) and create a corresponding model.</p><p><strong>Methods: </strong>A retrospective analysis of 362 patients from our hospital was performed. All patients were randomized into training and validation groups in a ratio of 7:3. Risk factors were screened using the least absolute shrinkage and selection operator (LASSO) and logistic regression analysis.</p><p><strong>Results: </strong>The analysis indicated that upper location, number of CLNM ≥ 3, rate of CLNM ≥ 0.172, prelaryngeal LNM, pretracheal LNM, and tall cell variant of papillary thyroid carcinoma (TCV-PTC) are independent risk factors. Visualizing the model with a nomogram, receiver operating characteristic (ROC) curves revealed an area under the curve (AUC) of 0.773 for the training group and 0.779 for the validation group. This confirms the stability and outstanding accuracy of the model. Also, the calibration curves and clinical descision curves reflect strong calibration,offering potential clinical benefits.</p><p><strong>Conclusions: </strong>The risk factors for LLNM include metastasis to the prelaryngeal lymph nodes, metastasis to the pretracheal lymph nodes, location in the upper level, number of metastases ≥3 in CLNM, TCV-PTC and metastasis rate ≥0.172. A nomogram incorporating these factors exhibits excellent predictive value and stability.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"185-193"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary hyperparathyroidism in patients with thyroid cancer: prevalence and prognosis in a retrospective monocentric study.","authors":"I Patelli, M Comina, L Musso, A De'Luca Di Pietralata, L Vera, M Minuto, M Albertelli, M Giusti, M Bagnasco, D Ferone, S Gay","doi":"10.1007/s12020-024-04142-2","DOIUrl":"10.1007/s12020-024-04142-2","url":null,"abstract":"<p><strong>Purpose: </strong>Primary hyperparathyroidism (PHPT) is associated with long-term implications on many aspects of general health and has been linked to various tumor types. This retrospective monocentric study aimed to evaluate the prevalence of primary hyperparathyroidism in a cohort of thyroid cancer patients and its impact on their general prognosis.</p><p><strong>Methods: </strong>The prevalence of primary hyperparathyroidism (concomitant or subsequent) was retrospectively evaluated in a cohort of 450 patients with a diagnosis of differentiated thyroid cancer. Its association with oncological outcomes and overall survival was analysed.</p><p><strong>Results: </strong>Among the study population, 30 patients (6,7%) were diagnosed with primary hyperparathyroidism. This subgroup displayed older age at diagnosis and a higher prevalence of prior cardiovascular disease, other primary tumors and multinodular goiter (p < 0.001). PHPT was associated with increased mortality; however, no significant difference in thyroid cancer-specific mortality was found.</p><p><strong>Conclusion: </strong>A significant proportion of thyroid cancer patients may present concomitant primary hyperparathyroidism, which appears to negatively affect long-term prognosis, independently from their oncological outcomes.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"304-314"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone and muscle mass characteristics in patients with gastroenteropancreatic neuroendocrine neoplasms.","authors":"Charalampos Aktypis, Maria P Yavropoulou, Efstathios Efstathopoulos, Despina Polichroniadi, Kalliopi Anna Poulia, George Papatheodoridis, Gregory Kaltsas","doi":"10.1007/s12020-024-04140-4","DOIUrl":"10.1007/s12020-024-04140-4","url":null,"abstract":"<p><strong>Background: </strong>Neuroendocrine neoplasms (NEN) are rare tumors arising from neuroendocrine cells most commonly in the gastrointestinal-tract. In recent years, advancements in therapeutics have increased survival rates in patients with NEN leading to a greater clinical burden compared to the general population.</p><p><strong>Methods: </strong>The aim of this single-center case-control study was to investigate the incidence of low bone mass and changes in body composition in adult patients diagnosed with gastroenteropancreatic neuroendocrine tumors (GEPNET). Enrolled participants underwent measurements of bone mineral density (BMD) at the lumbar spine (LS), femoral neck (FN), and total hip (TH) and body composition analysis with calculation of total fat-mass (TFM) and relative skeletal mass index (RSMI), by dual X-ray absorptiometry.</p><p><strong>Results: </strong>Ninety GEPNET patients (28 with Pancreatic-NET, 20 with small-intestine-NET, 42 with gastric-NET), and 50 age and sex-matched controls were enrolled. The mean disease duration was 5±4.4 years, the majority of patients (54/90) was classified as stage-1, and were not receiving systemic-treatment (76/90). The incidence of osteoporosis/osteopenia was threefold higher in the patients' cohort, compared to controls (OR: 3.17 95% CI 1.16-7.8, p < 0.001). Among NEN patients, gastric-NET had the lowest bone mass, especially in LS. In addition, GEPNET patients demonstrated significantly lower TFM and RSMI, compared to controls (TFM: 31.6 ± 9.6 kg vs. 38.6 ± 6.4 kg, respectively, p = 0.03; RSMI: 6.4 ± 1.1 vs. 8.2 ± 0.6, respectively, p < 0.001). Within our patients' cohort, RSMI was significantly associated with LS-BMD (rho = 0.49, p < 0.001) and TH-BMD (rho = 0.58, p < 0.001), and TFM was associated with TH-BMD (rho = 0.31, p = 0.004).</p><p><strong>Conclusions: </strong>Patients with GEPNET even at an early stage exhibit significantly lower bone, muscle and fat mass compared to the non-NET population, highlighting the importance of continuous monitoring of the musculoskeletal system in these patients.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"348-358"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound-based radiomics to predict the volume reduction rate of benign thyroid nodules after microwave ablation.","authors":"Fang Chen, Yuxiu Gao, Qingwen Xue, Xiaoyan Niu, Xiaojuan Zhang, Yichen Zang, Hui Zhang, Shuao Li, Cheng Zhao","doi":"10.1007/s12020-024-04125-3","DOIUrl":"10.1007/s12020-024-04125-3","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the predictive power of ultrasound-based radiomics models for benign thyroid nodules with a volume reduction rate (VRR) of < or ≥75% at 12 months after microwave ablation.</p><p><strong>Methods: </strong>A retrospective study was conducted on 194 individuals with benign thyroid nodules who received ultrasound-guided microwave ablation between November 2019 and June 2023. The clinical and ultrasound features, including age, gender, volume, echogenicity, duration of ablation, and so on were analysed by t-test or chi-square test. Radiomics features were extracted from longitudinal and transverse ultrasound images of the nodules. The features were selected using methods such as least absolute shrinkage and selection operator (LASSO). Radiomics models were established using longitudinal, transverse, and longitudinal + transverse ultrasound images to predict the VRR of benign thyroid nodules after ablation. Decision curve analysis (DCA) and receiver operating characteristic (ROC) curve analysis were used to assess the models' performance.</p><p><strong>Results: </strong>At 12 months following ablation, the VRR of the nodules was 77.8 ± 19.4% (7.4-98.8%). Statistical analysis revealed that the duration of ablation and the proportion of liquid extracted were significantly correlated with the 12-month VRR (P <0.05). In the radiomics models, Logistic Regression (LR) performed the best. In the training cohorts, the area under the curve (AUC) for the longitudinal, transverse, and combined groups were 0.935, 0.800, and 0.937. The AUC values in the test cohort were 0.820, 0.844, and 0.917.</p><p><strong>Conclusion: </strong>The radiomics models established based on pre-ablation ultrasound images showed good predictive efficacy for the VRR of nodules at 12 months following ablation. The predictive efficacy is best in the combined group. With the models, we can preoperatively predict patients' prognoses and thereby determine whether to proceed with ablation therapy.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"162-174"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anillin interacts with RhoA to promote tumor progression in anaplastic thyroid cancer by activating the PI3K/AKT pathway.","authors":"Shi-Tong Yu, Bai-Hui Sun, Jun-Na Ge, Zhi-Gang Wei, Zhi-Cheng Zhang, Wei-Sheng Chen, Ting-Ting Li, Shang-Tong Lei","doi":"10.1007/s12020-024-04145-z","DOIUrl":"10.1007/s12020-024-04145-z","url":null,"abstract":"<p><strong>Background: </strong>Anaplastic thyroid cancer (ATC) is the most aggressive thyroid malignancy and has an extremely poor prognosis, necessitating novel therapeutic strategies. This study investigated the role of anillin (ANLN) in ATC, focusing on its impact on tumor growth and metastasis through the RhoA/PI3K/AKT signaling pathway.</p><p><strong>Methods: </strong>TCGA and GEO datasets were analyzed to identify key molecular alterations in thyroid cancer. ANLN expression was assessed in clinical samples. Functional assays, including CCK-8, colony formation, scratch, and Transwell invasion assays, and mouse xenograft models, were conducted to evaluate the biological role of ANLN. Coimmunoprecipitation, immunofluorescence, and active Rho GTPase pull-down assays, as well as phosphorylation antibody arrays, were used to explore the underlying mechanisms.</p><p><strong>Results: </strong>Analysis of TCGA and GEO datasets revealed that ANLN is upregulated in thyroid cancers, including ATC and PTC, with higher ANLN expression correlating with worse survival outcomes. Functional studies demonstrated that ANLN promoted ATC cell proliferation, migration, and invasion. In vivo, ANLN knockdown inhibited tumor growth in xenograft models. Mechanistically, ANLN directly interacted with RhoA, facilitating its activation and subsequent stimulation of the PI3K/AKT signaling pathway. The tumorigenic effects of ANLN were suppressed by AKT inhibition with afuresertib or RhoA silencing.</p><p><strong>Conclusion: </strong>ANLN plays a crucial role in ATC progression by activating the RhoA/PI3K/AKT pathway, suggesting its potential as a therapeutic target in ATC.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"211-222"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vivo and in vitro evidence for a protective role of autoantibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' orbitopathy.","authors":"Giulia Lanzolla, Giovanna Rotondo Dottore, Simone Comi, Giada Cosentino, Dalì Antonia Ciampa, Elena Sabini, Francesca Menconi, Maria Novella Maglionico, Chiara Posarelli, Roberto Rocchi, Francesco Latrofa, Michele Figus, Ferruccio Santini, Michele Marinò","doi":"10.1007/s12020-025-04219-6","DOIUrl":"https://doi.org/10.1007/s12020-025-04219-6","url":null,"abstract":"<p><strong>Purpose: </strong>The insulin-like growth factor-1 receptor (IGF-1R) plays a role in the pathogenesis of Graves' orbitopathy (GO). A possible protective role of autoantibodies against IGF-1R (IGF-1R-Abs) on GO has been suggested.</p><p><strong>Methods: </strong>We conducted a cross-sectional study to investigate IGF-1R-Abs in 147 consecutive Graves' disease (GD) patients, with (n = 92) or without (n = 55) GO (primary outcome), their relationship with GO features and their effect on cell proliferation in primary cultures of orbital fibroblasts.</p><p><strong>Results: </strong>Serum IGF-1R-Abs levels were higher (29.3 ng/mL, IQR 17.4-36.6) in patients without GO than in those with GO (19.8 ng/mL, IQR 11.2-29.8; Mann Whitney U 1819, P = 0.00509). The prevalence of IGF-1R-Abs levels above the previously established cut-off value of 55 ng/mL did not differ statistically between the two groups, despite a trend towards a greater prevalence in patients without GO (9 vs 3.2%) (Fig. 1b). Within GO patients, serum IGF-1R-Abs did not correlate with proptosis, CAS, eyelid width and visual acuity, whereas there was an inverse correlation with diplopia, being IGF-1R-Abs lower in patients with the most severe degrees (Omega square = 0.0123, P = 0.035). Incubation of orbital fibroblasts from GO patients with IgGs purified from a pool of sera with IGF-1R-Abs > 55 ng/mL decreased cell proliferation in a dose-dependent manner (Omega square = 0.747; P < 0.0001).</p><p><strong>Conclusions: </strong>Serum autoantibodies against the IGF-1R are present in a minority of patients with GD and seem to exert a protective role on GO development and features.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy, safety, and risk factors of thermal ablation for follicular thyroid neoplasms: a multicentric study.","authors":"Xin-Yi Zhou, Bo-Qiang Fan, Jun-Feng He, Ying Zhou, Song-Song Wu, Shu-Rong Wang, Gang Dong, Jian-Qin Guo, Ying Wei, Zhen-Long Zhao, Jie Wu, Shi-Liang Cao, Na Yu, Yan Li, Li-Li Peng, Ming-An Yu","doi":"10.1007/s12020-025-04213-y","DOIUrl":"https://doi.org/10.1007/s12020-025-04213-y","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the efficacy and safety of thermal ablation (TA) in managing follicular thyroid neoplasms (FN).</p><p><strong>Methods: </strong>This multicenter retrospective study involved participants diagnosed with FN across nine hospitals, undergoing microwave ablation or radiofrequency ablation from January 2014 to January 2024. Primary outcomes assessed were technical success and disease progression, with secondary outcomes including tumor size and volume changes, complete tumor disappearance, complications, and side effects. Subgroup analyses aimed to identify factors influencing tumor progression and complete disappearance.</p><p><strong>Results: </strong>The study enrolled 375 patients (mean age: 43.2 years ± 14.9 [standard deviation]; 298 women) with 482 FNs, tracked over an average of 23.6 months, achieving a 100% technical success rate. Disease progression was observed in 4.8% (18/375) of patients, with a local recurrence rate of 3.7% (14/375) and new neoplasm occurrence of 1.1% (4/375). Multifocal neoplasms emerged as an independent risk factor for disease progression (hazard ratio [HR], 3.48; 95% CI, 1.16-10.45; P = 0.026). Tumor volume significantly reduced (P < 0.001), particularly within 1-3 months post-ablation, with complete tumor disappearance observed in 10.4% (39/375) of cases, more likely in tumors smaller than 2 cm (HR, 0.11; 95% CI, 0.06-0.23; P < 0.001). Complications occurred in 2.9% of patients, with major events in 2.1% and minor in 0.8%.</p><p><strong>Conclusion: </strong>TA is a safe and efficacious method for treating FN, showing low rates of disease progression and complications. Optimal outcomes may be achieved in patients with unifocal FN and neoplasms under 2 cm.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between admission serum calcium levels and in‑hospital mortality in acute myocardial infarction patients with cardiovascular-kidney-metabolic syndrome.","authors":"Jing Xu, Shuai Yu, Jian Huang, Li Geng, Yumiao Wei, Xin Li, Xin Gong","doi":"10.1007/s12020-025-04217-8","DOIUrl":"https://doi.org/10.1007/s12020-025-04217-8","url":null,"abstract":"<p><strong>Purpose: </strong>Acute myocardial infarction (AMI) with cardiovascular-kidney-metabolic (CKM) condition is linked to a high in-hospital mortality. Some previous studies reported that calcium may be related with in-hospital mortality among patients with AMI. However, there is no report about the association between serum calcium and AMI patients with CKM syndrome. Therefore, this study investigated the association between admission serum calcium levels and in-hospital mortality in a cohort of AMI patients with CKM syndrome.</p><p><strong>Methods: </strong>This retrospective cohort study enrolled 2537 admitted patients with AMI including 270 patients with CKM. All the data were extracted from electronic medical records from May 2019 to April 2024. According to the reference range of serum calcium, all the 270 patients were divided into two groups, low calcium group (0-2.10 mmol/L) and non-low calcium group (from 2.11 mmol/L). The primary endpoint was in-hospital mortality.</p><p><strong>Results: </strong>The in-hospital mortality rate was significantly higher in the low calcium cohort (16.8%, n = 19) compared to the non-low calcium group (8.3%, n = 13). After adjusting for age, gender, hypertension, atrial fibrillation, stroke and smoke, patients in the low calcium group demonstrated significantly higher in-hospital mortality compared to the non-low calcium group (OR = 2.409, 95% CI: 1.105-5.249, p < 0.05). In subgroup analyses, the multivariable logistic regression models indicated that serum calcium was an independent predictor for in-hospital mortality in females (OR = 7.453; 95% CI = 1.751-31.730; p < 0.05) and elderly patients (OR = 3.122; 95% CI = 1.167-8.348; p < 0.05) after adjustments for hypertension, atrial fibrillation, stroke and smoke. Restricted cubic splines (RCS) regression analysis showed a dose-response relationship between serum calcium and in-hospital mortality (nonlinear P value = 0.067).</p><p><strong>Conclusions: </strong>Admission hypocalcemia is an independent risk factor of in-hospital mortality in AMI patients with CKM syndrome, especially in elderly individuals (aged ≥76 years) and females.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of vitamin D₃ and calcium supplementation on bone of young adults after thyroidectomy of differentiated thyroid carcinoma.","authors":"Lei Sun, Xiaoyun Lin, Naishi Li, Qian Zhang, Yan Jiang, Ou Wang, Weibo Xia, Xiaoping Xing, Xiaoyi Li, Mei Li","doi":"10.1007/s12020-025-04195-x","DOIUrl":"https://doi.org/10.1007/s12020-025-04195-x","url":null,"abstract":"<p><strong>Purpose: </strong>Differentiated thyroid carcinoma (DTC) is the most frequent endocrine cancer, with a high incidence in young population. Patients with postoperative DTC are usually considered with increased risk of bone loss, possibly due to the thyroid stimulating hormone (TSH) suppression therapy. However, it remains unclear whether vitamin D and calcium supplementation is beneficial on bone metabolism of young patients with vitamin D malnutrition after thyroidectomy of DTC.</p><p><strong>Methods: </strong>In this one-year prospective study, adult men younger than 50 years or premenopausal women with DTC and vitamin D insufficiency or deficiency were enrolled after thyroidectomy, who were administered with daily supplements of 1000-2000 IU vitamin D₃ and 600 mg of elemental calcium (calcium-D₃) or not. Propensity score matching (PSM) was applied to identify baseline-matched cohorts.</p><p><strong>Results: </strong>A total of 458 patients with a median age of 37 (range 21-50) years were enrolled, with 94 (20.5%) patients supplemented with calcium-D₃. After PSM, we identified baseline-matched cohorts of 246 DTC patients, of which 82 patients were supplemented with calcium-D₃ and 164 were not. After 12 months' supplementation, lower serum levels of β-CTX (0.27 ± 0.15 vs. 0.35 ± 0.18 ng/ml, P = 0.004), PTH (36.2 ± 12.7 vs. 45.2 ± 14.6 pg/ml, P < 0.001) and higher BMD at lumbar spine (1.8% vs. 0.7%, P = 0.050) and total hip (1.1% vs. -0.4%, P < 0.001) were observed compared to the control group. Among all the 458 patients, increase of 25OHD levels was closely associated with decrease of PTH, ALP and β-CTX levels and improvement in total hip BMD throughout the one-year study period.</p><p><strong>Conclusion: </strong>Vitamin D and calcium supplements can reduce PTH levels and bone loss, possibly contributing to protecting bone of young DTC patients with vitamin D malnutrition after thyroidectomy.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}